Data and facts on generic substitution and therapeutical standardization;Data en feiten over generieke substitutie en therapeutische standaardisatie

Pharmaceutisch Weekblad

Volumn 132, Issue 10, 1997, Pages 290-294

  Tinke, J L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; AMOXICILLIN; ATENOLOL; CALCIUM ANTAGONIST; CODEINE; DIAZEPAM; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; FERROUS FUMARATE; FLUINDOSTATIN; FUROSEMIDE; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LORAZEPAM; NAPROXEN; NITRAZEPAM; OXAZEPAM; PARACETAMOL; PRAVASTATIN; PREDNISONE; SIMVASTATIN; TEMAZEPAM; TRIAMCINOLONE ACETONIDE;

DRUG COST; DRUG EFFICACY; DRUG MARKETING; PHARMACY; PRESCRIPTION; SHORT SURVEY; STANDARDIZATION;

EID: 0030846493     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (3)

1. Jaaroverzicht Zorg 1996. 's-Gravenhage: Ministerie van Volksgezondheid, Welzijn en Sport, 1996.
2. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994;343:1554-5.
3. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743-59.